LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

Inicio・Lista de Acciones・Krystal Biotech Inc

Krystal Biotech Inc

Abierto

SectorSanidad

298.39 -2.53

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

297.98

Máximo

306.33

Métricas clave
By Trading Economics
Ingresos	4.5M 56M
Ventas	9.3M 116M
P/B Media del Sector	41.829 51.415
BPA	1.83
Margen de beneficios	48.069
Empleados	295
EBITDA	16M 55M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+3.17% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.2B 9.2B
Apertura anterior	300.92
Cierre anterior	298.39

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

28 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

133.221 / 169.73 Soporte y Resistencia

Krystal Biotech Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 may 2026, 23:53 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 may 2026, 23:50 UTC

Charlas de Mercado

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 may 2026, 23:36 UTC

Charlas de Mercado

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 may 2026, 23:07 UTC

Adquisiciones, fusiones, absorciones

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

UOB: Share Sale Agreements Entered With Singland Properties

17 may 2026, 23:05 UTC

Adquisiciones, fusiones, absorciones

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire Stake for $389 Million

17 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 may 2026, 16:27 UTC

Adquisiciones, fusiones, absorciones

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 may 2026, 15:26 UTC

Adquisiciones, fusiones, absorciones

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 may 2026, 08:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparación entre iguales

Cambio de precio

Krystal Biotech Inc previsión

Precio Objetivo

By TipRanks

3.17% repunte

Estimación a 12 Meses

Media 316 USD 3.17%

Máximo 378 USD

Mínimo 284 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Krystal Biotech Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Krystal Biotech Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

133.221 / 169.73Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentimiento

By Acuity

28 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.